Breakthrough in Pulmonary Drug Delivery will Bring Numerous In-Hospital Treatments to the Home
JEFFERSON, N.C., December 19, 2007 /PRNewswire/ -- Next Safety, Inc., a leader in developing pulmonary drug delivery devices, today announced verification of a significant breakthrough in pulmonary science that provides high efficacy delivery of drugs to the lungs.
Advanced optical characterization techniques performed by a third party laboratory showed that 99.8% of the droplets delivered by Next Safety's pulmonary drug delivery devices were between one and three microns in diameter, and the droplets separated sufficiently in space and time to be absorbed into the alveoli of the lungs.
The company has already demonstrated more rapid delivery of nicotine to the bloodstream through the lungs than possible with cigarettes.
Next Safety's advance means that: -- Drugs previously restricted to intravenous or oral delivery such as antibiotics, analgesics, anti-emetics, peptides and proteins like insulin and vaccines can be delivered to the human body directly through the lungs. -- The pharmaceutical industry can offer medications with systemic delivery without needles, syringes and intravenous lines.
Four of the ten largest global pharmaceutical companies have expressed interest in the company's pulmonary business. Next Safety expects to begin a bidding process for its pulmonary business in early 2008.
Next Safety's immediate and ongoing research studies focus on the pulmonary delivery of nicotine, albuterol, tobramyacin and long chain peptide and protein molecules. Nicotine delivery and other clinical findings from brain imaging and arterial blood studies conducted in partnership with a major U.S. medical institution will be announced in the first quarter of 2008.
"Previous nicotine replacement products have helped millions of smokers worldwide. However the delivery mechanisms of these products cannot equal the power of nicotine delivered through the smoked cigarette. The next step in nicotine replacement treatment is the ability to deliver nicotine directly to the lung and brain, in the same manner as a cigarette, without the 4,000 harmful chemicals in tobacco" said Matthew Bars, MS, CTTS, an expert in nicotine addiction, key opinion leader and consultant to the pharmaceutical industry and Next Safety, Inc. Mr. Bars is the Director of the New York City Fire Department's Tobacco Cessation Program. "Pulmonary delivery of 'clean' nicotine would become the gold standard of nicotine replacement therapies. The Next Safety pulmonary nicotine delivery device has the potential of saving the lives of hundreds of millions of smokers worldwide" Bars concluded.
For more information about Next Safety, Inc. or the bidding process, please visit our website www.nextsafety.com.
CONTACT: Christy Cheek of Next Safety, Inc., +1-336-246-7700, email@example.com
Web site: http://www.nextsafety.com/
Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company
Posted: December 2007